Calprotectin

Fecal calprotectin and serum C-reactive protein biomarkers can inform disease management for patients with asymptomatic or symptomatic Crohn’s disease, according to an updated clinical practice guideline from the AGA.

The proteomic profile of breast milk of women with inflammatory bowel disease may affect an infant’s microbiome development and fecal calprotectin, according to a presenter at the Congress of the European Crohn’s and Colitis Organization.

Calprotectin was found to be related to ultrasound synovitis scores in patients with rheumatoid arthritis treated with interleukin-6 inhibitors and janus kinase inhibitors, according to a poster presented at ACR Convergence 2021.

The combination of fecal immunochemical test-based colonoscopy and fecal calprotectin detected advanced colorectal neoplasia, according to a presentation at Digestive Disease Week.

A presenter at the Crohn’s and Colitis Congress highlighted the importance of biomarkers in determining disease activity in inflammatory bowel disease, especially in the era of COVID-19.